SELLAS Life Sciences Group (SLS) is a late-stage clinical biopharmaceutical company developing immunotherapeutics for blood cancers and solid tumors. Its lead asset, galinpepimut-S (GPS), is a WT1-targeting cancer vaccine licensed from Memorial Sloan Kettering Cancer Center, while a second program, SLS009 (tambiciclib), is a CDK9 inhibitor in Phase 2 testing for acute myeloid leukemia.
The stock fell 19.16% to $14.51, down from Wednesday's close of $17.95. The decline was triggered by the company's decision to price a $150 million equity raise at $13.00 per share, a steep discount to the market price, just one day after a pivotal trial win had more than doubled the share price.
SELLAS priced an underwritten public offering of 11,538,462 shares at $13.00 each, for gross proceeds of $150 million before fees. Underwriters hold a 30-day option for up to 1,730,769 additional shares, which would lift gross proceeds to about $172.5 million. J.P. Morgan and TD Cowen are joint book-running managers, with Mizuho, A.G.P. and Maxim Group also in the syndicate. The offering is expected to close Nov. 20.
The $13.00 clearing price sits 27.6% below Wednesday's close and roughly 32% below Tuesday's post-data close of $19.15. That discount is the mechanical center of today's move: new buyers are being given a price far below where existing holders transacted, and the stock is now converging toward the deal level. Proceeds are earmarked for clinical development of the company's product candidates, commercial launch preparation, and general corporate purposes.
SELLAS held $134.7 million in cash and equivalents at Sept. 30 and reported a third-quarter net loss of $10.1 million, so the raise is not a distress signal — which is precisely why some holders objected to the size of the discount accepted so soon after a favorable trial readout.
Tuesday's rally remains the backdrop. The Phase 3 REGAL trial of GPS met its primary overall survival endpoint, showing a median survival of 24.0 months versus 14.7 months for best available treatment, a hazard ratio of 0.59, a two-sided p-value of 0.035, and a 41% reduction in the risk of death. The stock closed that session at $19.15, up 156% from $7.47, after trading as high as $24.89.
Shares gave back 6.27% on Wednesday as the offering was launched, and today's move extends the reversal. From Tuesday's close, the stock has now shed about 24%. With the company guiding toward an FDA meeting and a Biologics License Application in the first half of 2027, there is no new negative clinical or regulatory development behind the selling — the pressure is financing-driven and momentum-driven.
Maxim raised its price target on SLS to $40 from $30 while maintaining a Buy rating following the REGAL results, and Alliance Global moved higher on the name earlier in the week. Constructive sell-side coverage supports the longer-term thesis, but it does nothing to offset the immediate dilution and the repricing effect of a large block of stock sold at $13.00.
The move is idiosyncratic. The biotech benchmark XBI traded roughly flat on the session, the Russell 2000 small-cap index slipped about 0.9%, and the S&P 500 eased around 0.2%. No sector-wide or macro catalyst explains a decline of this magnitude.
Volume was heavy. Roughly 6.4 million shares traded in the first hour, already exceeding the 60-session average daily volume of about 5.2 million, following 50.3 million shares on Tuesday and 20.6 million on Wednesday. The stock gapped down, opened at $15.39, pushed to an intraday high of $16.54, and then faded to a low near $14.48 — a failed rebound that leaves the $13.00 offering price as the key reference level. Even after the pullback, the shares are up about 285% year to date and sit far above the 52-week low of $1.39, with a market capitalization near $3.1 billion.
The score runs from 0 to 100: 0 means no meaningful news and a move that is normal for the stock, while 100 means transformative news paired with an extreme, rare price move. SLS earns 49 out of 100.
The catalyst was substantial but not transformative: a $150 million financing priced at a 27.6% discount is a major event for a company of this size, though it follows rather than alters the clinical narrative. The price move was meaningful but not extraordinary by this stock's standards — roughly 2.7 times its typical daily swing over the past 60 sessions, and only the second move of comparable size in that window. A major financing combined with a moderately unusual move lands the score in the middle of the range.
The offering is scheduled to settle Nov. 20, and the days around settlement often determine whether $13.00 holds as support or becomes overhead supply. Management has said it will meet with the FDA to discuss an accelerated filing pathway, with a Biologics License Application targeted for the first half of 2027; any detail on that timetable is the next fundamental checkpoint. On the pipeline side, preliminary topline data from the Phase 2 study of SLS009 in newly diagnosed, first-line AML is expected in the fourth quarter, and Phase 2 relapsed/refractory data will be presented at the American Society of Hematology meeting in December.
Risks are concentrated. The investment case rests heavily on a single late-stage asset, regulatory outcomes remain uncertain, and the enlarged share count modestly dilutes per-share economics. Sell-side views have turned more constructive since the data, but sentiment toward clinical-stage biotech can reverse quickly, and post-offering volatility is common.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as conditions shift. Readers looking for systematic ways to monitor volatile names like this one can review the current lineup and compare performance data before deciding which approaches fit their own objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for SLS moved out of overbought territory on November 19, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 33 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 76 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.596). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology